Form 4: Denali Capital Global Investments Sells 500,000 Class B Ordinary Shares in Denali Capital Acquisition Corp.

Denali Capital Global Investments LLC sold 500,000 Class B ordinary shares of Denali Capital Acquisition Corp. to Scilex Holding Company as part of a Sponsor Interest Purchase Agreement.

Summary

• Denali Capital Global Investments LLC, a 10% owner of Denali Capital Acquisition Corp. (DECA), filed a Form 4.
• On August 30, 2024, Denali Capital Global Investments sold 500,000 Class B ordinary shares of DECA.
• The sale was to Scilex Holding Company as part of a Sponsor Interest Purchase Agreement (SIPA).
• The consideration for the shares included $2,000,000 in cash and 300,000 shares of Scilex common stock.
• The cash consideration was paid on August 30, 2024, and the Scilex shares are contingent upon the merger between Denali Merger Sub Inc. and Semnur Pharmaceuticals, Inc., a subsidiary of Scilex.
• Following the transaction, Denali Capital Global Investments LLC directly owns 1,432,500 Class B Ordinary Shares.

Sentiment

Score: 5

Explanation: Neutral sentiment as it reports a transaction involving the sale of shares as part of a merger agreement. No clear positive or negative implications are apparent.

Future Outlook

The issuance of Scilex shares to Denali Capital Global Investments LLC is contingent upon the completion of the merger between Denali Merger Sub Inc. and Semnur Pharmaceuticals, Inc.

Industry Context

This transaction is related to a business combination (merger) between a special purpose acquisition company (SPAC), Denali Capital Acquisition Corp., and a pharmaceutical company, Semnur Pharmaceuticals, Inc. SPAC mergers are a common way for private companies to go public.

Related Party Transactions

• The sale of shares to Scilex Holding Company, a related party due to the merger agreement, constitutes a related party transaction.

Stakeholder Impact

• Shareholders of Denali Capital Acquisition Corp. will be impacted by the merger with Semnur Pharmaceuticals, Inc.
• Scilex Holding Company shareholders will be impacted by the issuance of new shares as part of the transaction.

Next Steps

• Completion of the merger between Denali Merger Sub Inc. and Semnur Pharmaceuticals, Inc.
• Issuance of 300,000 shares of Scilex common stock to Denali Capital Global Investments LLC upon completion of the merger.

Key Dates